EUVIMEDEUVIMED entdecken
Kohortenstudie

Financial and Clinical Toxicity of Empiric Vancomycin for Intra-Abdominal Infections: A Cohort Study

Laura M Ebbitt, Jeremy D VanHoose, Samantha Manci, Aric Schadler, Abigail Leonhard, Jitesh A Patel

Surgical Infections · 2025

DOI: 10.1089/sur.2024.269 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Surgical Infections, 2025. Verfasst von Laura M Ebbitt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Vancomycin, Anti-Bacterial Agents, Intraabdominal Infections, Staphylococcal Infections. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vancomycin for intra-abdominal infections (IAI) should be reserved for healthcare-acquired infections, history of multiple interventions, or methicillin-resistant Staphylococcus aureus (MRSA). The MRSA incidence is low; however, fear of missing MRSA leads to overutilization.

Methods

This single-center retrospective cohort study evaluated the cost and risks of empiric vancomycin for IAI. The primary objective was to determine the incidence of MRSA-positive culture and surveillance testing. Secondary outcomes included acute kidney injury (AKI) incidence, progression to dialysis, direct costs of vancomycin overutilization, length of stay, and 30-day mortality.

Results

A total of 1,045 patients with IAI were identified and 491 (47%) received at least one dose of vancomycin. Thirty patients (2.9%) grew MRSA. Of those who grew MRSA, 21 (70%) were MRSA positive on the surveillance multi-drug resistance (MDR) culture or by polymerase chain reaction during hospitalization. There were no deaths within the MRSA group. AKI developed in 351 (33.6%) patients during their hospitalization, with 49.6% occurring within 48 hours of vancomycin administration. Of the 65 patients (6.9%) who required dialysis, 27 patients (42%) received vancomycin. The cost of unnecessary doses equated to $21,655 and $188,643.84 for vancomycin levels.

Conclusion

Given the low MRSA culture incidence, it is reasonable to avoid vancomycin as empiric treatment for those being admitted for IAI alone to reduce the risk of AKI and reduce healthcare costs. Vancomycin should be limited mainly to those with a positive MRSA culture with consideration of vancomycin in those at highest MRSA risk such as a history of MRSA or known MRSA colonization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinAnti-Bacterial AgentsIntraabdominal InfectionsStaphylococcal InfectionsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedMethicillin-Resistant Staphylococcus aureusAged, 80 and overAdultAcute Kidney InjuryIncidence

Stichwörter der Autor:innen

empiric antibiotic agentsintra-abdominalintra-abdominal infectionsvancomycin

Substanzen

VancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, Kentucky, USA.
  • Department of Pharmacy Practice & Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, USA.
  • Department of Pediatrics Services, University of Kentucky HealthCare, Lexington, Kentucky, USA.
  • Dr. Bing Zhang Department of Statistics, College of Arts and Science, University of Kentucky, Lexington, Kentucky, USA.
  • Division of Colorectal Surgery, University of Kentucky College of Medicine, Lexington, Kentucky, USA.

Zitieren

APA

Ebbitt, L. M., VanHoose, J. D., Manci, S., Schadler, A., Leonhard, A., & Patel, J. A. (2025). Financial and Clinical Toxicity of Empiric Vancomycin for Intra-Abdominal Infections: A Cohort Study. Surgical Infections. https://doi.org/10.1089/sur.2024.269

Vancouver

Ebbitt LM, VanHoose JD, Manci S, Schadler A, Leonhard A, Patel JA. Financial and Clinical Toxicity of Empiric Vancomycin for Intra-Abdominal Infections: A Cohort Study. Surgical Infections. 2025. doi:10.1089/sur.2024.269

BibTeX
@article{Ebbitt2025,
  author = {Ebbitt, Laura M and VanHoose, Jeremy D and Manci, Samantha and Schadler, Aric and Leonhard, Abigail and Patel, Jitesh A},
  title = {Financial and Clinical Toxicity of Empiric Vancomycin for Intra-Abdominal Infections: A Cohort Study},
  journal = {Surgical Infections},
  year = {2025},
  doi = {10.1089/sur.2024.269}
}
Kostenlos starten →